Insurance Denied Your Wegovy or Zepbound. What Actually Works Next

There's a running thread in the weight-management communities we studied where people literally compare denial letters: whose insurer said "not medically necessary," whose demanded six months of documented diet attempts, whose plan simply excludes the entire drug class. It's the right instinct, because GLP-1 denials come in genuinely different species, and the single most common mistake is fighting an exclusion like it's a denial, or paying list price when a covered indication or a $299 program existed. Sort your letter first; everything follows from it.

Step 1: Is it a denial or an exclusion?

• A coverage denial says things like "not medically necessary," "prior authorization required," "step therapy: try X first," or "insufficient documentation." The plan covers the drug class; it's arguing about you. This is winnable with paperwork.
• A benefit exclusion says "weight-loss medications are not a covered benefit under this plan." Employers choose this to control costs, and it's increasingly common: GoodRx's coverage tracker found the number of commercially insured people with no Wegovy coverage grew 42% into 2026 (41+ million people), with over 109 million lacking Zepbound coverage. Appeals argue about medical necessity, and an excluded benefit fails before necessity is even considered.
• Not sure which you have? Call member services and ask directly: "Is this drug excluded from my plan's formulary entirely, or denied for my case?" Also ask what IS covered for weight management. Two minutes, and it picks your lane.

Fighting a denial: the documentation that wins

GLP-1 prior authorizations usually hinge on a checklist the insurer will read to you if asked (our prior auth guide covers the general machinery). Make the submission match it exactly:

1. The qualifying numbers, in the chart: BMI at or above the plan's threshold (commonly 30, or 27 with comorbidities), with the comorbidities (hypertension, prediabetes, high cholesterol, sleep apnea) explicitly documented by diagnosis code.
2. Prior attempts, documented: plans want evidence of lifestyle programs or prior medications. If you did Weight Watchers, a dietitian, metformin, phentermine, get it into the record with dates; undocumented history doesn't exist to a reviewer.
3. Step therapy? Fight or comply fast: if the plan demands a cheaper drug first, your doctor can request an exception with reasons it's inappropriate, or you try it and document the failure, which converts into approval ammunition.
4. Appeal a final no through the standard internal appeal and external review, with a letter of medical necessity that mirrors the plan's own criteria language.

The covered-indication angle (read this before paying cash)

Plans that exclude "weight loss" often still cover the same molecules for other FDA-approved uses. This is a conversation for your doctor, prescribing must follow the actual diagnosis, but it's medicine worth doing properly:

• Type 2 diabetes: semaglutide (Ozempic) and tirzepatide (Mounjaro) are widely covered for diabetes. If your A1c is in or near the diabetic range, that workup matters for coverage and for your health.
• Cardiovascular risk: Wegovy carries an FDA-approved indication for reducing cardiovascular risk in adults with obesity and established heart disease, an indication many plans (and Medicare) treat differently from weight loss.
• Obstructive sleep apnea: Zepbound is FDA-approved for moderate-to-severe OSA in adults with obesity. If you've been putting off the sleep study, it now has coverage implications.

On Medicare: the rules just changed

Federal law still bars Part D from covering drugs prescribed for weight loss itself (medicare.gov's summary). Two big carve-outs: Part D plans can cover GLP-1s for diabetes and for other approved indications like cardiovascular risk or OSA. And starting July 1, 2026, the Medicare GLP-1 Bridge program gives eligible beneficiaries access to certain GLP-1s for about $50 a month through 2027. If you're on Medicare and were told a flat no, ask your Part D plan about covered indications, and ask 1-800-MEDICARE about Bridge eligibility.

The exclusion lane: your real options

• Manufacturer self-pay dropped hard after the shortages: LillyDirect sells Zepbound single-dose vials at roughly $299 (starter) to $449 (maintenance) per month, and Novo's NovoCare pharmacy sells Wegovy at $499, no insurance involved. Check the manufacturer's own program before any middleman.
• Ask HR, seriously: employers add and drop this benefit annually based on demand. A short written request to benefits ("I'd like weight-management medication coverage considered at renewal") is more influential than people assume, especially in aggregate.
• FSA/HSA funds apply to prescription GLP-1s, softening self-pay with pre-tax dollars.
• Skip compounded semaglutide from wellness sites: with the shortages resolved, mass compounding of these drugs has lost its legal basis, and quality is unverifiable. The manufacturer programs above cost similar money for the real thing.
• Ask what IS covered: older generics (phentermine, bupropion-naltrexone) and covered lifestyle programs aren't equivalent, but with your doctor they can be a documented bridge, which doubles as the "prior attempts" record if coverage arrives later.